203866-14-2 Usage
Description
BOC-TRANS-4-FLUORO-L-PROLINE, a white powder, is a synthetic intermediate with significant applications in the pharmaceutical industry. It is known for its role in the preparation of potent 3or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors and the synthesis of pyrrolotriazines derivatives, which serve as pan-Aurora kinase inhibitors and anti-tumor agents.
Uses
Used in Pharmaceutical Industry:
BOC-TRANS-4-FLUORO-L-PROLINE is used as a synthetic intermediate for the development of various pharmaceutical compounds. It plays a crucial role in the preparation of:
1. Dipeptidyl Peptidase IV Inhibitors:
BOC-TRANS-4-FLUORO-L-PROLINE is used as a key component in the synthesis of potent 3or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. These inhibitors are essential for the treatment of type 2 diabetes and related metabolic disorders, as they help regulate blood glucose levels by increasing insulin secretion and decreasing glucagon release.
2. Pan-Aurora Kinase Inhibitors and Anti-Tumor Agents:
BOC-TRANS-4-FLUORO-L-PROLINE is also utilized in the synthesis of pyrrolotriazines derivatives, which act as pan-Aurora kinase inhibitors. These inhibitors are vital in the development of anti-tumor agents, as they target Aurora kinases, a family of serine/threonine protein kinases that play a significant role in cell cycle regulation and are often overexpressed in various cancers. By inhibiting Aurora kinases, these agents can help control tumor growth and progression, offering potential therapeutic benefits in cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 203866-14-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,8,6 and 6 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 203866-14:
(8*2)+(7*0)+(6*3)+(5*8)+(4*6)+(3*6)+(2*1)+(1*4)=122
122 % 10 = 2
So 203866-14-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H16FNO4/c1-10(2,3)16-9(15)12-5-6(11)4-7(12)8(13)14/h6-7H,4-5H2,1-3H3,(H,13,14)/t6-,7+/m1/s1
203866-14-2Relevant articles and documents
COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES
-
Page/Page column 237, (2017/04/29)
The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidi
NOVEL AMINO PYRIMIDINE DERIVATIVES
-
Page/Page column 68; 69; 70, (2015/06/11)
The present invention describes new amino pyrimidine derivatives of formula (I) and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
Incorporation of fluoroprolines to proctolin: Study on the effect of a fluorine atom toward peptidic conformation
Kitamoto, Takamasa,Ozawa, Taeko,Abe, Megumi,Marubayashi, Shunsuke,Yamazaki, Takashi
, p. 286 - 293 (2008/12/22)
In spite of quite small steric perturbation, substitution of proline (Pro) in the target pentapeptide proctolin (Arg-Tyr-Leu-Pro-Thr) for (4R)- as well as (4S)-4-fluoroproline led to apparent alteration of the pyrrolidine ring structure which eventually r
